Skip to main content

Advertisement

Table 1 Splenocyte immunophenotypes after treatment with Pioglitazone in vitro and in vivo

From: Pioglitazone alters monocyte populations and stimulates recent thymic emigrants in the BBDZR/Wor type 2 diabetes rat model

  In vitro In vivo
Non-diab. Non-diab. + Pio Non-diab. Non-diab. + Pio Diabetic Diabetic + Pio
CD3+ 14.4 % ± 0.4 17.8 % ± 1.0* 86.4 % ± 2.8 86.2 % ± 0.5 10.7 % ± 3.0* 64.3 % ± 3.3*
CD3+CD4+ 12.7 % ± 0.7 3.7 % ± 0.3# 53.1 % ± 10 50.0 % ± 8.8 11 % ± 8.4# 27.3 % ± 3.9#
CD3+CD4+CD25+ 6.6 % ± 0.4 33.1 % ± 3.4 12.4 % ± 1.8 19.0 % ± 0.5 4.6 % ± 2.1 36.2 % ± 7.1
  1. Splenocytes were labeled with rat anti-CD3 AF-647, anti-CD4 PE-Cy7, and anti-CD25 FITC. Results are % ± SD, n = 3
  2. In vitro non-diabetic + Pio versus non-diabetic: * p = 0.0085, # p = 0.0006,  p = 0.0022
  3. In vivo diabetic versus non-diabetic (1): * p = 0.0087, # p = 0.0043,  p = 0.0040
  4. Diabetic + Pio versus Diabetic (2): * p = 0.0135, # p = 0.0302,  p = 0.0178